Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: current status and future possibilities.

Journal of the National Cancer Institute. Monographs Pub Date : 2023-05-04 DOI:10.1093/jncimonographs/lgad003

Mary C Playdon, Sheetal Hardikar, Prasoona Karra, Rachel Hoobler, Anna R Ibele, Katherine L Cook, Amanika Kumar, Joseph E Ippolito, Justin C Brown

{"title":"Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: current status and future possibilities.","authors":"Mary C Playdon, Sheetal Hardikar, Prasoona Karra, Rachel Hoobler, Anna R Ibele, Katherine L Cook, Amanika Kumar, Joseph E Ippolito, Justin C Brown","doi":"10.1093/jncimonographs/lgad003","DOIUrl":null,"url":null,"abstract":"<p><p>Obesity is a chronic, relapsing, progressive disease of excess adiposity that increases the risk of developing at least 13 types of cancer. This report provides a concise review of the current state of the science regarding metabolic and bariatric surgery and obesity pharmacotherapy related to cancer risk. Meta-analyses of cohort studies report that metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care. Less is known regarding the cancer-preventive effects of obesity pharmacotherapy. The recent approval and promising pipeline of obesity drugs will provide the opportunity to understand the potential for obesity therapy to emerge as an evidence-based cancer prevention strategy. There are myriad research opportunities to advance our understanding of how metabolic and bariatric surgery and obesity pharmacotherapy may be used for cancer prevention.</p>","PeriodicalId":73988,"journal":{"name":"Journal of the National Cancer Institute. Monographs","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157771/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Institute. Monographs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jncimonographs/lgad003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Obesity is a chronic, relapsing, progressive disease of excess adiposity that increases the risk of developing at least 13 types of cancer. This report provides a concise review of the current state of the science regarding metabolic and bariatric surgery and obesity pharmacotherapy related to cancer risk. Meta-analyses of cohort studies report that metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care. Less is known regarding the cancer-preventive effects of obesity pharmacotherapy. The recent approval and promising pipeline of obesity drugs will provide the opportunity to understand the potential for obesity therapy to emerge as an evidence-based cancer prevention strategy. There are myriad research opportunities to advance our understanding of how metabolic and bariatric surgery and obesity pharmacotherapy may be used for cancer prevention.

查看原文本刊更多论文

代谢和减肥手术以及预防癌症的肥胖症药物疗法：现状和未来的可能性。

肥胖症是一种慢性、复发性、进行性的脂肪过多疾病，会增加至少 13 种癌症的患病风险。本报告简明扼要地回顾了代谢和减肥手术以及肥胖症药物治疗与癌症风险相关的科学现状。队列研究的元分析表明，与非外科肥胖治疗相比，代谢和减肥手术与较低的癌症发病风险有独立关联。至于肥胖症药物疗法的癌症预防效果，目前还知之甚少。最近批准的肥胖症药物和前景广阔的肥胖症药物管线将为了解肥胖症疗法作为一种循证癌症预防策略的潜力提供机会。我们有无数的研究机会来促进我们对代谢和减肥手术以及肥胖药物疗法如何用于预防癌症的了解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the National Cancer Institute. Monographs

CiteScore

6.30

自引率

0.00%

发文量